Efficiency of a fixed combination of insulin glargine and lixisenatide in everyday clinical practice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: In order to intensify therapy, hypoglycemic drugs that provide not only optimal glycemic control, but also have non-glycemic properties can be used.

Objective. Evaluation of the glycemic and non-glycemic effects of the fixed combination (FC) of insulin glargine and lixisenatide in patients with type 2 diabetes mellitus (DM2) in everyday clinical practice over 24 months of follow-up.

Materials and methods. The study included 35 DM2 patients who did not achieve compensation of carbohydrate metabolism during previous hypoglycemic therapy. Patients were prescribed the FC of insulin glargine and lixisenatide. Anthropometric data, parameters of carbohydrate metabolism and lipid spectrum, and hemodynamic parameters were analyzed initially and after 24 months. Additionally, the frequency of symptomatic hypoglycemic states and severe hypoglycemia was assessed.

Results. After 24 months of treatment with FC of insulin glargine and lixisenatide, glycemic control parameters were improved without weight gain and hypoglycemic episodes, lipid metabolism parameters with a positive effect on systolic blood pressure.

Conclusion: FC of insulin glargine and lixisenatide not only provide optimal glycemic control, but are also capable of exerting a number of pleiotropic effects in the form of weight loss, improved lipid parameters and systolic blood pressure.

Full Text

Restricted Access

About the authors

Olga S. Elsukova

Kirov State Medical University

Email: oselsukova@mail.ru
ORCID iD: 0000-0002-2341-9491

Cand. Sci. (Med.), Associate Professor at the Department of Hospital Therapy

Russian Federation, Kirov

Elena A. Nikitina

Kirov State Medical University

Author for correspondence.
Email: nikitinae1991@mail.ru
ORCID iD: 0000-0002-7316-3252

Cand. Sci. (Med.), Associate Professor, Department of Internal Medicine

Russian Federation, Kirov

References

  1. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. М., 2023. [Dedov I.I., Shestakova M.V., Mayorov A.Yu., et al. Standards of specialized diabetes care. M., 2023. (In Russ.)]. doi: 10.14341/DM13042.
  2. Демидова Т.Ю., Никитин И.Г., Кисляк О.А. и др. Роль агонистов рецепторов глюкагоноподобного пептида-1 в управлении кардиометаболическим здоровьем. FOCUS Эндокринология. 2024;5(4):76–88. [Demidova T.Yu., Nikitin I.G., Kislyak O.A., et al. The role of glucagon-like peptide-1 receptor agonists in cardiometabolic health management. FOCUS Endocrinology. 2024;5(4):76–88. (In Russ.)]. doi: 10.62751/2713-0177-2024-5-4-22.
  3. Самойлова Ю.Г., Станкова А.Е., Матвеева М.В. и др. Фармакогенетика агонистов глюкагоноподобного пептида-1 в лечении сахарного диабета 2 типа. Профилактическая медицина. 2023;26(12):95–100. [Samoilova Iu.G., Stankova A.E., Matveeva M.V., et al. Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus. Rus J Prevent Med. 2023;26(12):95–100. (In Russ.)]. doi: 10.17116/profmed20232612195.
  4. Куркин Д.В., Бакулин Д.А., Морковин Е.И. и др. Фиксированные комбинации агонистов рецепторов ГПП-1 и базального инсулина: Обзор литературы. Пробл. эндокринологии. 2024;70(1):91–9. [Kurkin D.V., Bakulin D.A., Morkovin E.I., et al. Fixed ratio combinations GLP-1RA and basal insulin: literature review. Probl Endocrinol. 2024;70(1):91–9 (In Russ.)]. doi: 10.14341/probl13312.
  5. Анциферов М.Б., Демидов Н.А., Балберова М.А. и др. Эффективность использования фиксированной комбинации инсулина гларгин 100 ЕД/мл и ликсисенатида у пациентов с сахарным диабетом 2 типа в условиях реальной амбулаторной практики: ретроспективное когортное исследование SOLO. Сахарный диабет. 2022;25(2):112–9. [Antsiferov A.B., Demidov N.A., Balberova M.A., et al. Real World Effectiveness of fixed combination of glargine 100 U/ml and lixisenatide therapy in outpatients with Type 2 Diabetes: A Retrospective Cohort Study SOLO. Diab Mellitus. 2022;25(2):112–9 (In Russ.)]. doi: 10.14341/DM12809.
  6. Мартьянова М.В., Бабенко А.Ю. Агонисты рецепторов глюкагоноподобного пептида-1, выбор внутри класса. Рациональная комбинация «инсулин гларгин 100+ликсисенатид». Медицинский совет. 2020;(7):50–5. [Martianova M.V., Babenko A.Yu. Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100+lixisenatide. Medical Council. 2020;(7):50–5. (In Russ.)]. doi: 10.21518/2079-701X-2020-7-50-55.
  7. Bala C., Cerghizan A., Mihai B.M., et al. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ. Open. 2022;27;12(5):e060852. doi: 10.1136/bmjopen-2022-060852.
  8. Демидова Т.Ю., Кожевников А.А. Агонисты рецепторов глюкагоноподобного пептида 1: безграничный потенциал применения. Доктор.Ру. 2020;19(2):6–12. [Demidova T.Yu., Kozhevnikov A.A. Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential. Doctor. Ru. 2020;19(2):6–12. (In Russ.)]. doi: 10.31550/1727-2378-2020-19-2-6-12.
  9. Risovic I., Dumanovic M.S., Bojic M., Djekic D. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC. Endocr Disord. 2023;23(1):28. doi: 10.1186/s12902-023-01282-w.
  10. Аметов А.С., Невольникова А.О., Тертычная Е.А. Возможности агонистов рецепторов глюкагоноподобного пептида-1 в снижении сердечно-сосудистого риска у пациентов с сахарным диабетом типа 2: что нового? Эндокринология: Новости. Мнения. Обучение. 2019;3(28):44–53. [Ametov A.S., Nevolnikova A.O., Tertychnaya E.A. Possibilities of glucagon-like peptide-1 receptor agonists in reducing cardiovascular risk in patients with type 2 diabetes mellitus: what’s new? Endocrinology: News, Opinions, Education. 2019;3(28):44–53. (In Russ.)]. doi: 10.24411/2304-9529-2019-13005.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure 1. Study design

Download (134KB)
Indexing metadata
3. Figure 2. Dynamics of HbA1c, fasting plasma glucose and postprandial glycemia in patients with type 2 diabetes treated with insulin glargine and lixisenatide

Download (53KB)
Indexing metadata

Copyright (c) 2025 Bionika Media